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Abstract
Runt related transcription factor 2 (RUNX2) is a key regulator of osteoblast differentiation. Several variations within the
RUNX2 gene have been found to be associated with significant changes in BMD, which is a major risk factor for fracture. In
this study we report that an 18 bp deletion within the polyalanine tract (17A.11A) of RUNX2 is significantly associated with
fracture. Carriers of the 11A allele were found to be nearly twice as likely to have sustained fracture. Within the fracture
category, there was a significant tendency of 11A carriers to present with fractures of distal radius and bones of
intramembranous origin compared to bones of endochondral origin (p = 0.0001). In a population of random subjects, the
11A allele was associated with decreased levels of serum collagen cross links (CTx, p = 0.01), suggesting decreased bone
turnover. The transactivation function of the 11A allele showed a minor quantitative decrease. Interestingly, we found no
effect of the 11A allele on BMD at multiple skeletal sites. These findings suggest that the 11A allele is a biologically relevant
polymorphism that influences serum CTx and confers enhanced fracture risk in a site-selective manner related to
intramembranous bone ossification.
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Introduction
Increased fracture rates are found in patients with lower bone
mineral density (BMD), although many fractures occur in patients
who are not considered osteoporotic [1,2]. Fracture risk is not fully
explained by BMD as factors that are environmental and genetic
are also involved [3]. Although the genetic architecture of fracture
risk is complex and polygenic, a reasonable candidate gene is
RUNX2: the protein RUNX2 is a critical regulatory factor in
osteoblast and chondrocyte differentiation and essential for skeletal
development [4–7]. RUNX2 is expressed in mesenchymal progen-
itors and promotes hypertrophy of chondrocytes [4–7] and directs
the differentiation of osteoblasts [8]. The combined functions of
bone extracellular matrix formation and mineralization regulate
bone volume and mineral density. RUNX2 associates with a beta
subunit (Cbfb) and forms transcriptional complexes to either
activate or inhibit the transcription of target genes [9]. Such
function transactivation assays have been used to correlate severity
of RUNX2 mutations with function [10].
Heterozygous mutations in coding and promoter regions of
RUNX2 in humans [4–7] cause the skeletal syndrome Cleidocra-
nial Dysplasia (CCD) [11]. CCD develops when one allele of
RUNX2 is entirely functional and the other compromised, a state
known as haploinsufficiency; indicating that RUNX2 levels are
limiting in skeletal development. CCD is characterized by
hypoplasia/aplasia of clavicles, persistently open or delayed
closure of sutures, Wormian bones, supernumerary teeth, short
stature and other skeletal abnormalities [11]. Certain bones are
more affected than others in CCD: notably the clavicle, scapula,
face/mandible, pelvis depending on the severity of the RUNX2
mutation [10,11]. During development, particular bones form by
either endochondral or intramembranous ossification or a
combination of both processes [12]. The bones most affected in
CCD, such as scapula, face/mandible, pelvis and clavicle, have a
high content of intramembranous ossification [12]. Runx2 knock-
out mouse homozygotes fail to develop osteoblasts and have no
mineralized bone. In the case of haploinsufficiency in mice, greater
defects are observed in bones with a higher content of
intramembranous ossification compared to bones of greater
endochondral origin, mirroring the subtly of human CCD.
Regardless of the distinction between intramembranous and
endochondral routes of formation, a feature of CCD is a
characteristic range of bones that are affected in a particular rank
order of severity. Studies of Runx2 gene dosage using isoform
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specific knockout mice support the hypothesis that Runx2-II (an
isoform driven off the P1 promoter) is more important for
endochondral bone formation than the Runx2-I isoform (driven
by the P2 promoter) [13]. To that point, mice with intact
Runx2-I isoform survive with reduced bone density and are able
to increase cortical bone over time, with a form of low bone
turnover osteopenia [13]. However, mice with defects in the P1
promoter (which is induced in osteoblasts) that generate gene
dose effects also mirror the defects in CCD with more
pronounced defects in bones with a high content of intramem-
branous ossification [14]. Currently, these data taken together
suggest that local tissue specific effects occur and that different
ossification types (endochondral versus intra-membranous) are
differentially affected by either RUNX2 isoform and/or RUNX2
gene dosage. Based on these propositions, we present the
hypothesis that genetic variants of RUNX2 with functional
effects may manifest in relative differences of intramembranous
bone versus endochondral bone. Although a number of genetic
markers exist in RUNX2 [4–7], we selected a coding region
variant for study: a six amino acid deletion in a poly alanine
tract that is a candidate functional polymorphism. Even if the
distinction between intramembranous and endochondral bone
ossification is not as great as supposed, functional variants of
RUNX2 may present with a rank order of affected bones similar
to the rank order of affected status found in CCD. However, if
this hypothesis is correct, then different rates of fracture may be
expected in bones of primarily endochondral origin relative to




Geelong Osteoporosis Study (GOS): one component of the
GOS comprises a prospective population-based epidemiology
study with age-stratified random recruitment from the Barwon
Statistical Division (population 216,000), as described previously
[15,16]. DNA, serum markers and bone densitometry DXA data
were obtained for 822 females. Markers of bone turnover CTx
(collagen telopeptide) and BSAP (bone alkaline phosphatase) were
available on 803 and 799 subjects, respectively. DXA was
performed using Lunar DPX-L densitometer and analyzed using
Lunar DPX-L software version 1.31. BMD was measured at the
spine (L2–L4) in the posterior-anterior projection, proximal femur
(femoral neck, Ward’s triangle, trochanter), whole body, ultradistal
(UD) and mid-forearm sites. Bone mineral apparent density
(BMAD) was calculated for the spine (L2-4) as BMC/(area)1.5
according to Carter et al [17]. Self-reported fracture history was
obtained by questionnaire.
The GOS random population survey study subjects were
recruited via the electoral roll and thus represent an unbiased
random population survey. Follow up data were available: the
cohort was followed prospectively and incident fractures occurring
during the five year period following baseline identified from all
radiological reports in the study region, using a validated keyword
search strategy [18]. Furthermore, fractures resulting from high
impact events such as motor vehicle accidents, were excluded.
Within the postmenopausal females of the random population-
based sample, a group existed (n = 224) that did not have incident
fracture in the five year surveillance period and had reported an
absence of adult fracture history at recruitment; representing a
control non-fracture postmenopausal group with a mean age of
72610 (6 standard deviation, SD) years similar to that of GOS
fracture cases (70612 SD).
GOS fracture cases (GOS fracture): all residents of the Barwon
Statistical Division who sustained incident fracture over a two year
period were identified from radiology practices servicing the
region, as previously described [19]. All fracture case were
approached to join the study. DNA was taken from female
fracture patients over 35 years of age with fractures of all types. In
order to reduce confounding variables, this study is limited to post-
menopausal females. A total of 598 fracture patients were
genotyped. The International Classification of Diseases, 9th
revision (ICD 9) was used to code fractures. For GOS and GOS
fracture, written informed consent was obtained under the
procedures of the Declaration of Helsinki, approved by the
Barwon Health Human Research Ethics Committee.
South East Queensland bone study (SEQBS): the study is based
at Southport in Queensland, Australia. SEQBS study participants
were recruited via notices in the local newspaper, resulting in 980
volunteers. DNA was extracted from leukocytes using salt
precipitation methods and genotype data obtained from 671
samples. For all subjects, anthropometric measures and a detailed
history was taken of age of menarche, parity, menopausal status,
smoking, and other history of illness. Fracture history was obtained
through detailed questionnaire including minor or major severity
of impact associated with injury, location of fracture and age at
fracture. DXA data were not available. In addition, subjects had
data on 23 standard serum and urine metabolic measures
including alkaline phosphatase. Written informed consent was
obtained and procedures were approved by the Griffith University
Human Research Ethics Committee, following the guidelines of
the Declaration of Helsinki.
Serum measures of bone turnover
Serum from subjects of GOS and SEQBS were taken after
overnight fast and stored at 280C. Enzyme-linked immunoassay
was used to determine serum concentrations of cross-linked
collagen products (CTx) and bone specific alkaline phosphatase
(BSAP) [20,21].
Detection of alleles in RUNX2 polyQ/polyA repeat
sequence
Convention specifies that, for the human, the gene is termed
RUNX2 and the protein termed RUNX2. Primers were: forward
59-AGC CTG CAG CCC GGC AAA ATG AGC-39, reverse 59-
GGG TGG TCG GCG ATG ATC TCC ACC ATG-39. PCR
amplified DNA was resolved on 7.5% polyacrylamide enabling
accurate detection of deletion genotypes as described [22]. All
DNA samples were genotyped twice on two different occasions.
Some DNA samples failed to amplify and therefore were not
genotyped. There was no apparent pattern to those DNA that
failed.
Plasmids, cell culture and luciferase assay
Full length RUNX2 type-I cDNA (pEF-aA) [23] served as a
template to construct RUNX2 11A allele cDNA. PCR was used to
amplify the RUNX2 11A from a homozygous individual using the
primers 59-TTCACCACCGGACTCCAACT-39 for the 59 side
and 59-CATCTGGTACCTCTCCGAGGGCTACCACCTT-
GAAGGCCACGGGCAGGGTC-39 for the 39 side. The reverse
primer contained an EcoNI tag facilitating the cloning of the PCR
amplified product into the BglII-EcoNI site of pUC18RUNX2
[24]. The 11A RUNX2 cDNA was confirmed by DNA
sequencing and was excised from pUC18 using XbaI restriction
digest and cloned into the XbaI site of pEF-Bos. The human
osteocalcin promoter vector pOSLUX (590 base pairs of the
RUNX2 Alanine Repeat and Fracture
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promoter upstream of fire-fly luciferase) was as described [24].
pRRE (meaning Runx-Responsive Element, and made for this
study) contains three copies of the consensus RUNX2 binding
element from the mouse osteocalcin gene upstream of firefly
luciferase driven by a minimal promoter. Other constructs for
glutamine variants 16Q and 30Q were described previously [24].
Cell lines were obtained from the American Type Culture
Collection (ATCC). Transfection experiments and cell culture
conditions were as described previously [24]. In summary, cell
lines (NIH3T3 and HEK293) were cultured DMEM with 10%
fetal bovine serum (v/v), 1% Penicillin-Streptomycin (v/v) in a 5%
CO2 humidified atmosphere at 37uC. Transfections were done
using FuGENE6 according to the manufacturer’s protocol
(Promega) as described previously [24] and luciferase assays
according to Dyer et al [25]. Confocal microscopy was used to
measure the extent of nuclear localization when transfected into
COS7 cells; a cell line chosen due to low endogenous RUNX2 and
ease of transfection. Cells were counted and categorized according
to whether staining was nuclear, cytoplasmic or nuclear and
cytoplasmic using a RUNX2 antibody.
Statistical Analysis
Fisher’s exact test and Pearson’s chi-square test of association
were used to analyze the allele frequencies between fracture and
non-fracture groups. Probabilities (p values) are presented for the
association of alleles (17A versus 11A) and the carrier status (11A/
11A homozygotes considered equivalent to 17A/11A heterozy-
gotes) using odds ratios (OR). In analysis of sub-categories of
fracture, Fisher’s exact test was used to provide the probability
under the assumption that defective RUNX2 variants would
predispose to greater defect (reflected in higher fracture rates) at
bones of greater intramembranous content, as had been observed
in mice [14]. Logistic regression was used to study the effects of
covariates on binary outcomes. In the GOS randomly-selected
sample, analysis of variance (ANOVA) was used to compare
subject anthropomorphic measurements and the general linear
model was used to compare BMD and biochemical markers of
bone turnover between the different RUNX2 genotype groups
while adjusting for the covariates age and weight. Fisher’s
protected least significant difference test was used for post-hoc
comparisons, after a prior significant omnibus ANOVA F-test.
Student’s t-tests or ANOVA were used to analyse the quantitative
transactivation analysis data. The general linear model was used
for exploration of multifactorial relationships and to analyse
transfection data with complex treatments. Equality of variance
assumptions were met by logarithmic transformation, where
necessary and verified using Levene’s test. Fisher’s method was
used to combine p values in independent studies: (22 times the
sum of loge p values is distributed as a chi-square with 2 k degrees
of freedom, where k is the number of studies).
Results
Relationship of RUNX2 11A allele to risk of fracture GOS
RUNX2 alleles were observed at a frequency of 0.93, and 0.07
for 17A and 11A alleles, respectively. A significant difference was
observed (p = 0.020, Table 1) in allele frequencies of 17A and 11A
between the control no-fracture group with female fracture cases
from the same region (the Barwon Statistical Division) with an
increase of the 11A allele in the fracture group relative to the non-
fracture group. The 11A allele frequency was 0.04 in the control
non-fracture group and 0.07 in all fracture cases. Control subjects
were recruited from the same population (GOS) and had not
sustained fracture during the observation interval and had
reported no history of adult fracture. When allele frequencies
were compared between all fracture cases and controls, the OR for
fracture related to the 11A allele was 1.9 with a confidence interval
(95% CI) of 1.1 to 3.2.
Relationship of 11A allele to risk of fracture SEQBS study
In the South East Queensland Bone study (SEQBS), at a
different geographical location within the same country, self
reported history of fracture prior to the study was available for all
genotyped subjects. The allele frequencies were 0.94 and 0.06 for
17A and 11A alleles respectively. There were no significant
differences in height, age or weight between the fracture and non-
fracture groups (males and females analyzed separately). RUNX2
11A carrier status (11A heterozygotes and 11A homozygotes) was
associated with fracture in the entire group (p = 0.033, OR = 1.71,
95% CI = 1.04–2.83). This effect was driven by association in the
females (p = 0.025, OR = 2.01, 95% CI = 1.08–3.75). The effect in
females was driven by stronger association in the post-menopausal
category (p = 0.005, OR = 2.91, 95% CI = 1.34–6.34) while in the
smaller number of premenopausal females in the study (n = 90)
there was no evidence of significant association with fracture.
In the GOS study, postmenopausal females from the random
population sample who had not reported facture on questionnaire
and who did not have fracture in a five year observation period
were taken as no-fracture controls. Drawn from within the
SEQBS, all female postmenopausal women who did not report
fracture represent a similar control group. Genotype and allele
counts were not significantly different (p = 0.14) from this SEQBS
no fracture post-menopausal group to that of GOS no fracture
controls, indicating in a second population that a control no
fracture group has a similar distribution of alleles. Comparison
between female controls and fracture cases showed significant
association of 11A with fracture (Table 1, allelic association
p = 0.005) with allele distributions similar to GOS. Although these
two populations were recruited from geographically separate parts
of the same country, the no fracture controls allele frequencies
were not significantly different (p = 0.14): Table 1 shows p values
for allelic association with fracture in the total data for Australian
post-menopausal females (p = 0.0007). Fisher’s method for com-
bining p values of independent studies gave a similar outcome
(p = 0.001).
Relationship of RUNX2 11A allele to fracture at different
bone sites
Data from both GOS and SEQBS showed similar association
with fracture for the 11A allele. Fractures at distal radius, ankle,
Table 1. Study, group, genotype counts, 11A allele frequency
(f[11A]) and p value using Pearson’s chi square of allele counts
in non-fracture control versus fracture cases in females from
two studies (GOS and SEQBS) and those studies combined.
Study Group 17A/17A 17A/11A 11A/11A f[11A] p value
GOS Control 207 17 0 0.04
Fracture 518 78 2 0.07 0.020
SEQBS Control 193 13 1 0.04
Fracture 71 14 1 0.09 0.005
Combined Control 400 30 1 0.04
Fracture 589 92 3 0.07 0.0007
doi:10.1371/journal.pone.0072740.t001
RUNX2 Alanine Repeat and Fracture
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spine, arm and hip were available from SEQBS: 11A status was
significantly related to distal radius (p = 0.002) and ankle (p = 0.01)
fracture location, but not other skeletal sites. The GOS fracture
study recruited a larger number of fractures and so has a greater
capacity to discriminate fracture location. A significant increase in
the frequency of 11A alleles was observed in distal radius fractures
relative to control non fracture cases (p = 0.02). The GOS fracture
group consisted of many fracture types (Table 2) with spine, distal
radius, hip, arm and ankle being the most frequent. The frequency
of the 11A allele within each particular fracture sub-group was
investigated. Scapular and clavicle fractures were combined as
fractures of the pectoral girdle. The allele frequencies for 11A were
determined for each anatomical fracture site; and the 11A allele
frequency ranged from zero to 0.25. When the 11A allele
frequencies were ranked from highest to lowest (Table 2) the rank
order of frequency of 11A alleles according to fracture site follows
the sites of the skeleton most affected by the syndrome CCD. The
rank order from highest to lowest for 11A allele frequency in
fracture sub-groups was: face/mandible, ribs, clavicle/scapula,
pelvis and metacarpals. These bones are also the most strongly
affected in CCD, dependent on the severity of the particular
mutation [11].
The GOS fracture cases were sorted according to the site of
fracture and those bones related to the more extreme CCD
symptoms were combined. Bones defined as ‘‘CCD-related’’ were:
ribs, face/mandible, scapula, clavicle, pelvis, metacarpals, pha-
langes (n = 78) compared to all other fracture types (n = 520).
Within all fracture cases there was a significant preference for
fracture at CCD-related bones within 11A carriers (p = 0.002,
OR = 2.3, 95% CI = 1.4 to 4.0), compared to fracture at non
CCD-related bones. When fractures in bones thought to have a
higher proportion of intra-membranous ossification were consid-
ered (scapula, clavicle, face/mandible, sternum and ribs), com-
pared to all other fracture types, a significant association with 11A
alleles was observed (p = 0.0001, OR = 3.0, 95% CI = 1.6 to 5.4).
Compared to controls, the association was more prominent: 11A
alleles were associated with fracture of bones derived primarily
from intra-membranous ossification compared to non-fracture
controls (p = 3.561026, OR = 4.8, 95% CI = 2.3 to 9.9). For bones
of primarily endochondral origin, two fracture types were available
that provided sufficient numbers (108 and 65 for spine and hip
fracture, respectively) to test the hypothesis that the 11A allele
alters the liability for fracture of a bone according to the majority
mode of ossification (either primarily intramembranous or
endochondral). The 11A allele was significantly associated
(p = 0.0001, OR = 3.9, 95% CI = 1.9 to 8.2) with fracture at
bones of a greater content of intramembranous ossification
compared with fracture of bones of higher endochondral
ossification (spine and hip combined) (Table 3). Therefore, within
fracture patients, 11A RUNX2 allele carriers have a higher
likelihood of fracture at certain CCD-related bones, of higher
intramembranous ossification, compared to wild type 17A allele-
carriers.
Relationship of RUNX2 11A allele to CTx and BSAP
markers
Markers of bone remodeling, serum CTx and BSAP, were
available from the random population subjects recruited from the
GOS. Carriers of the 11A allele had significantly lower ln(CTx)
measures (5.4760.91 SD, N = 91) compared to non-carriers
(5.7060.81 SD, N = 712, p = 0.018). When adjusted for age and
weight, 11A carriers retained significantly lower CTx serum levels
(p = 0.03). In contrast, there were no significant differences in
ln(BSAP) levels between 11A carriers and non-carriers (p = 0.706).
Adjusting for the significant covariates age and weight had no
material effect on the result (p = 0.715). CTx was not available for
SEQBS: BSAP was not related to 11A status in this study
(p = 0.53).
Biochemical analysis of 11A RUNX2 expression construct
relative to 17A allele
Expression vectors in the context of the RUNX2-I isoform were
constructed containing either alternative allele of the alanine
repeat (17A or 11A) and used in a series of biochemical tests to
determine if significant differences existed between the isoforms.
Under identical conditions of transfection there was no significant
difference in the extent of nuclear localization of either isoform
(p = 0.18), where the majority of staining was nuclear (Fig. 1A).
Table 2. Genotype counts, 11A allele frequency (fr[11A]) and
p value according to anatomical locations ranked by the
frequency of the 11A allele in the fracture group.
Fracture group 17A/17A 17A/11A 11A/11A fr[11A] p value1
All-fracture 518 78 2 0.07
Patella 5 0 0 0.00 0.682
Upper leg 8 0 0 0.00 0.545
Foot 30 2 0 0.03 0.280
Hip 60 5 0 0.04 0.203
Toe 11 1 0 0.04 0.385
Spine 97 11 0 0.05 0.117
Finger/thumb 17 2 0 0.05 0.268
Carpals 7 1 0 0.06 0.351
Humerus 33 5 0 0.07 0.118
Forearm 42 5 1 0.07 0.067
Ankle 40 7 0 0.07 0.063
Distal radius 91 16 0 0.07 0.020*
Lower leg 35 7 0 0.08 0.044*
Metacarpals 7 2 0 0.11 0.132
Pelvis 13 4 0 0.12 0.041*
Ribs, sternum 16 5 1 0.16 0.003*
Scapula/clavicle 3 2 0 0.20 0.054
Face/mandible 3 3 0 0.25 0.011*
1p value from Fisher’s exact test.
*denotes nominally significant effect.
doi:10.1371/journal.pone.0072740.t002
Table 3. RUNX2 11A allele is associated with fracture at
bones with cleidocranial dysplasia-related bones of higher
intramembranous ossification (pelvis, scapula, clavicle, ribs,
sternum, face/mandible) compared with common fractures in
bones of higher content of endochondral ossification (hip and
spine combined).
Fracture type 17A 11A fr[11A] p value
Intramembranous 84 16 0.160
Endochondral 330 16 0.048 0.0001
Allele counts, allele frequency (fr[11A]) and p value by Pearson’s chi-square.
doi:10.1371/journal.pone.0072740.t003
RUNX2 Alanine Repeat and Fracture
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However, under the condition of co-transfection of the co-
activator protein CBFB, which forms a heterodimer with
RUNX2, a significant difference (p = 161028) was observed
with less nuclear staining of CBFB in cells transfected with the
11A version of RUNX2 (Fig. 1B). In other words, a biochemical
difference was only revealed by the presence of CBFB co-
transfection, suggesting a reduced capacity to assist in CBFB
nuclear localization. Western blots using extracts from COS7
cells transfected with expression vectors showed equivalent
amounts of protein (Fig. 1C).
Quantitative transactivation analysis was carried out using a
RUNX2 target gene reporter assay. Based on power calculations,
five constructs and controls were compared, with 9 replicate
transfections done to detect minor effects. The HEK293 cell line
was used due to low endogenous RUNX2. RUNX2 23Q/11A
expression construct was compared with wildtype 23Q/17A and
two glutamine repeat variants that we had already established
were significantly different from the wild type (16Q/17A and
30Q/17A RUNX2 variants) [24]. As expected, the previously
reported significant decrease in 16Q and 30Q rare RUNX2
variants was verified using reporter plasmids pRRE (Fig. 2A) with
16Q and 30Q constructs being 76% and 69% active. Similarly,
compared to wildtype 23Q/17A, the 23Q/11A construct
produced significantly lower activity (p = 0.0004), being 77%
active overall in this assay.
Notably, a greater difference between RUNX2 17A and 11A
isoforms was also observed on the truncated p147 mouse
osteocalcin promoter, transfected into NIH3T3 fibroblast cells,
where the RUNX2 11A isoform had lower transactivation
capacity in the absence of CBFB (p = 0.001, Fig. 2B). Co-
transfection of CBFB partner protein essentially normalized the
effect to the level found in the 17A wild type isoform (p = 0.3).
These data support the hypothesis that the 11A variant of RUNX2
is slightly decreased in potential transcriptional activation of target
promoters and this effect varies according to the particular target
promoter examined and the presence of cofactor proteins such as
CBFB.
Considering that CBFB appeared to modulate the effect of the
RUNX2 11A allelic isoform in the expression construct relative to
17A, we explored the relationship by transfection with another
partner protein of RUNX2, the vitamin D receptor (VDR) using
the human osteocalcin promoter driving luciferase (pOSLUC) in
HEK293 cells. This experiment compared simultaneously two
constructs (RUNX2 17A and 11A) at three concentrations of
transfected construct (control zero, 15, 30 and 45 ng transfect-
ed), with or without transfected VDR (10 ng) and with or
without treatment with 1,25(OH)2D3 (at 10
27 M) with appro-
priate vehicle and empty vector controls, as duplicate transfec-
tions within each experiment [24]. This entire experimental
plan was repeated and assayed on four separate occasions. No
significant difference was observed in experimental repeats done
at different times: data were pooled and analyzed using the
general linear model taking into account all variables. VDR
transfection did not have an effect on basal activity of the target
pOSLUC in the absence of 1,25(OH)2D3: induction by
1,25(OH)2D3 in the presence of VDR was around three-fold.
Treatment with 1,25(OH)2D3 in the absence of transfected
VDR resulted in significant induction (1.6 fold, p = 3.961027)
presumably from endogenous VDR. The RUNX2 11A
construct had significantly lower capacity to drive pOSLUC
in HEK293 cells (p = 1.161026). The difference between
RUNX2 11A and 17A construct activity (Fig. 3) was significant
in the: (i) absence of both VDR and 1,25(OH)2D3 (p = 0.01); (ii)
absence of VDR and presence of 1,25(OH)2D3 (p = 0.001); (iii)
presence of VDR but absence of 1,25(OH)2D3 (p = 0.013). A
significant difference was not observed in the presence of VDR
transfection and treatment with 1,25(OH)2D3 (p = 0.24), sug-
gesting that activated VDR drives the promoter to an extent
that covers any potential difference between RUNX2 17A and
11A. Because of the decreased basal activity (Fig. 3) of the
RUNX2 11A construct driving pOSLUC there appears to be a
greater response to 1,25(OH)2D3 than the wild type 17A
construct (5.8 fold for 11A versus 3.1 fold for 17A). This means
that in the presence of VDR and 1,25(OH)2D3 treatment, the
difference between RUNX2 11A and 17A constructs is reduced
and no longer significant since VDR induction occurs in the
presence of both RUNX2 11A and 17A.
BMD relationship
The effect of the alanine deletion polymorphism on BMD was
investigated in the GOS random population subjects. BMD
information was available from seven skeletal sites and a total of
822 subjects with genotype: all individuals were included in
analysis. There were no significant differences in age, height and
weight between the RUNX2 genotype groups. The 11A allele did
not show a significant relationship with BMD at any of the skeletal
sites, including the distal forearm, in keeping with a prior
publication on a smaller set of the same cohort [22].
Figure 1. RUNX2 17A and 11A constructs have differential nuclear residence. A. Confocal immuno-fluorescence labeled with anti-RUNX2
antibody to detect nuclear or cytoplasmic residence. A comparison of RUNX2 17A and 11A reveals small differences in RUNX2 nuclear residence. B.
the ability of RUNX2 to enhance the nuclear localization of the partner protein CBFB is diminished in RUNX2 11A isoform. White numbers indicate
percentages of cells with that particular type of staining. C. Western blot indicating that expression vectors produce appropriate amounts of RUNX2
variants. Left and right panels are derived from the same gel, with intervening lanes removed; the left panel with mock transfected control and wild
type 17A control appeared previously [24].
doi:10.1371/journal.pone.0072740.g001
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Discussion
To expand our prior studies of the GOS group [22], in this
current work we doubled the sample of GOS random population
subjects that were genotyped and completed the genotype of all
available adjudicated fracture cases in the GOS fracture study. In
addition, we show a relationship with self-reported fracture in a
second independent cohort. In the GOS fracture cohort, we found
a site-specific relationship of the 11A allele with fracture that was
particular to bones with a greater content of intramembranous
ossification. A relationship with BMD was not found, although a
significant relationship with serum CTx in the GOS random
cohort is evidence for a physiological relationship at the level of
bone, since CTx is a marker of bone turnover [20]. A simple
explanation may be that the effect of the 11A variant on BMD is
small enough to escape detection in this study. The fact that we
observed a relationship with fracture at the distal radius, but did
not observe a relationship with BMD at this site suggests a non
BMD-related mechanism should be considered. It is possible that
the increased risk of fracture associated with the 11A allele is not
explained by changes in BMD, but relates to the process of
ossification and some unmeasured architectural parameter in
bone. The long bones including the distal radius contain a bone
collar where intramembranous ossification occurs and the
periosteum is described as defective in CCD [11,12]. Since the
bone sites where the RUNX2 11A allele is most associated with
fracture have a higher content of intramembranous ossification,
the relationship of 11A to bone density and structure needs to be
investigated in further studies, with that hypothesis in mind.
Aspects of RUNX2 function in bone may influence an individual’s
susceptibility to fracture by altering components of bone quality
that are independent of bone density as measured by DXA. While
site selectivity was shown with reasonable numbers in two studies
at the distal radius and ankle, a limitation of the study is that
smaller numbers of fractures in other bones were available.
Despite this, a simple classification system for the skeleton based
on those bones most affected in CCD produced a statistically
significant outcome, for increased fracture within bones of higher
intramembranous content versus high endochondral content for
carriers of the 11A allele.
There are limitations to this study. The fractures that comprise
the majority of the study (GOS fracture) are adjudicated from
medical records, but the second study (SEQBS) relied on self-
Figure 2. RUNX2 17A and 11A constructs have differential biochemical behavior. A. Transfection comparison of the activities of RUNX2
expression constructs driving RUNX2 sensitive reporter plasmid (p3RRE) in HEK293 cells. pBOS is empty vector control for baseline promoter activity
of the RUNX2 responsive plasmids. 23Q/17A construct (17A) has higher activity than the RUNX2 23Q/11A variant allele (11A). On the reporter (p3RRE)
the RUNX2 23Q/11A variant was significantly different from the wild type 23Q/17A allele (p = 0.0004) and was similar in expression to rare allelic
variants of the glutamine repeat (16Q/17A and 30Q/17A, labeled as 16Q and 30Q, respectively). B. Effect of CBFB cotransfection on the comparison
between RUNX2 17A and 11A constructs on a truncated mouse osteocalcin promoter, p147. A difference is observed between RUNX2 17A and 11A
constructs in the absence of CBFB. In the presence of CBFB, the p147 target promoter activity is induced and the difference between RUNX2 17A and
11A constructs is eliminated.
doi:10.1371/journal.pone.0072740.g002
Figure 3. Effect of VDR transfection on difference between
RUNX2 17A and 11A constructs in transfection. Constructs were
transfected at four concentrations (1, 15, 30 and 45 ng) with or without
VDR (10 ng) and with or without treatment with 1,25(OH)2D3 (1,25D3 in
figure) at 1027 M. Data presented are the marginal means derived from
the general linear model and adjusted by linear regression to 12.5 ng of
transfected vector. Error bars are one standard error of the mean.
Promoter activity is the control Renilla adjusted pOSLUC firefly
luciferase activity. In all cases within a treatment, is the comparison
between RUNX2 17A and 11A significantly different excepting the
single case marked where cells were transfected with VDR and treated
with 1,25(OH)2D3.
doi:10.1371/journal.pone.0072740.g003
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reported history. Although we did detect significant alterations in
RUNX2 activity, these were entirely in vitro assays in immortal cell
lines and involve transfections with expression vectors and
synthetic targets. There may be other target genes that show
greater differential activity or indeed, no differential activity.
Furthermore, this alteration in transactivation function may not be
related to the fracture phenotype; it is possible that some other
biochemical effect is occurring, specific to intramembranous
ossification. Similarly, the BMD measures were mostly not in
the bones that showed association with fracture. Although the
association with fracture is based on reasonable numbers, the
particular inferences that we draw concerning intramembranous
bones are based on smaller numbers (although significant) and
should be re-tested in large numbers. Finally, our study was biased
towards post-menopausal females, because the fracture rate is
higher in that group.
The 11A polymorphism is puzzling, being a protein coding
variant of an important transcription factor that exists at
reasonable frequency in the human population. Examination of
primate sequences indicates that the 17A allele is conserved and
presumably ancestral: Gorilla (22Q/17A) and chimpanzee
(25Q/17A) are different from human in the glutamine repeat,
while orangutan (23Q/17A) is identical to human. The Galago
(bushbaby, Otolemur crassicaudatus) is evolutionarily very distant
from humans, yet has 17 alanines (21Q/17A). Of 10 sequenced
species available, the only primate RUNX2 that is not 17A is
the mouse lemur (Microcebus murinus) with 16A. This indicates
remarkable stability of this sequence through time and reaffirms
the peculiarity of the 11A allele, which is unique to humans.
Given the conservation of the 17A configuration in the repeat
over evolutionary time, the possible function of the 11A allele is
intriguing. In the comparison between Neanderthal and modern
human DNA sequences, RUNX2 was indicated as highly
subjected to genetic selective sweep, indicating evolutionary
selection across this locus [26,27]. RUNX2 is therefore a
candidate gene for differences between Neanderthal and
modern human and a number of different functional changes
may be expected within RUNX2. The available Neanderthal
sequence is consistent with 17A in the repeat (see genome.ucs-
d.edu). Notable skeletal differences between Neanderthal and
modern human include ribs and mandible, sites with high
intramembranous content. Likewise, the available RUNX2
sequence of another archaic human, the Denisovan hominin
specimen [28], is consistent with the 17A allele (see geno-
me.ucsc.edu). How does our data relate to these points? The
RUNX2 11A allele may represent a rather new allelic variant,
perhaps influencing intramembranous versus endochondral
ossification, that is specific to modern humans.
The extent to which ossification at a particular bone is either
endochondral or intramembranous in character may be an
important factor in understanding the relationship of genes to
bone and bone fracture as a trait. Association of RUNX2 11A allele
with fracture exists in bones of greater intramembranous
ossification content: so called intramembranous bones [29]. The
same assemblage of bones is most affected in CCD, where
RUNX2 levels are inadequate in certain tissues due to
haploinsufficiency resulting in a critical threshold effect for
abnormality where 70% activity or less in mouse caused CCD
and greater than 79% activity resulted in normality [29,30].
Therefore it seems likely that the mechanism of RUNX2 11A allele
should relate to effective levels of RUNX2. This was supported by
our transfection studies that showed RUNX2 11A was less
effective at transcriptional activation through a transfection assay
and had differential measures of nuclear binding.
An alternative explanation is that RUNX2 11A is not a causative
variant but rather is in linkage disequilibrium with another
unknown variant that is responsible for the molecular mecha-
nism. Whole genome analysis shows association of BMD to the
RUNX2 genomic region [31]. Earlier studies indicated associ-
ation of RUNX2 alleles with bone phenotypes, BMD and
fracture in a number of different populations [22,24,32–38]. We
reported previously that the 11A allele arose in the common
ancestral P2 promoter haplotype [32], and that a rarer
haplotype variant of the P2 promoter with differential promoter
activity was associated with higher BMD. This association was
replicated in two separate Spanish cohorts [33,34], Russians
[35] and Koreans [36]. The P2 promoter drives RUNX2-I
isoform, which has been associated with intramembranous
ossification in mouse studies [39–41]. Differential activity of the
RUNX2 P2 promoter, changing the relative amount of the
RUNX2-1 isoform might be an attractive hypothesis to explain
differential fracture at bones of intramembranous ossification.
Therefore, although our transfection data indicates that the 11A
repeat polymorphism shows some functional differences, pro-
moter polymorphism is still a candidate explanation of the
association of 11A alleles with fracture: more studies are
required on this topic. Other evidence of clinically relevant
functional variation in RUNX2 include association with bone
length in hand and femur [35,37]. Comparing other species for
functional correlates of the Q/A repeat provides evidence that
the Q/A repeat itself has function. Functional evidence for
RUNX2 Q/A repeat variation include association with skull
shape specifically in dogs [42] and snout length more generally
in Carnivora [43]. Although this effect was not generalized across
all species of mammal [44] it was also significant in bill length
within species of the family Scolopacidae shorebirds [45].
Furthermore, in this study we verified our prior transfection
observations on RUNX2 glutamine repeat variants, which are
infrequent and have a greater effect in transfection compared
with the 11A variant. Taken together, these data suggest
RUNX2 as a locus of rich genetic variation related to skeletal
evolution across species and a source of clinically relevant
variation in humans.
In conclusion, the 11A allele of RUNX2 is a frequent
polymorphism (5% of alleles) related to increased risk of fracture.
In particular, the 11A allele predisposes to fracture of those bones
where a greater content of intramembranous ossification occurs.
The 11A deletion allele had a significant effect on CTx in the
GOS random population subjects but not BSAP. A direct effect of
the deletion polymorphism on the transactivation ability of
RUNX2 was observed. These findings suggest that the 11A
deletion is a biologically significant polymorphism altering bone
parameters and conferring an increased risk of fracture in a site
selective manner. Further to this point, we suggest that future
whole genome analysis of fracture take into account fracture
subtypes based on categories of intramembranous bone ossifica-
tion.
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